CCL2 and COVID-19: Compared to CAP patients, COVID-19 patients had higher IP-10 (median [IQR] 4986.8 [3044.8–8938.3] vs 749.2 [383.7–1740.8], P: < 0.001), IL-10 (36.2 [14.7–66.0] vs 10.6 [4.9–18.8], P: < 0.001), IL-6 (29.0 [9.4–60.2] vs 4.3 [0.0–47.0], P: 0.001), MCP-1 (562.4 [340.8–829.1] vs 321.2 [210.0–503.4], P: < 0.001), and IL-1α (85.7 [40.3–261.1] vs 49.7 [32.2–131.2], P: 0.03).